BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Messori A, Conti M, Fadda V, Maratea D, Trippoli S. Meta-regression of treatments for metastatic colorectal cancer: Quantifying incremental benefit from 2000 to 2012. World J Clin Oncol 2014; 5(2): 191-193 [PMID: 24829867 DOI: 10.5306/wjco.v5.i2.191]
URL: https://www.wjgnet.com/2218-4333/full/v5/i2/191.htm
Number Citing Articles
1
Andrea Messori, Mauro De Rosa, Valeria Fadda, Luca Pani. Effectiveness and Cost Effectiveness of Bevacizumab in Metastatic Colorectal CancerJournal of Clinical Oncology 2015; 33(32): 3838 doi: 10.1200/JCO.2015.61.8991
2
Andrea Nicolini. Biomarkers and the ‘target therapies’ in oncology, research and businessBiomarkers in Medicine 2017; 11(3): 217 doi: 10.2217/bmm-2016-0216
3
Alberto Russi, Vera Damuzzo, Marta Serena, Frida Gorreja, Angelo C. Palozzo. Improving the Management of High Cost Anticancer Drugs in a Health Care SystemGlobal & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 2016; 3(3): grhta.5000243 doi: 10.5301/grhta.5000243
4
Cindy Neuzillet, Benoît Rousseau, Hemant Kocher, Philippe Bourget, Christophe Tournigand. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomasPharmacology & Therapeutics 2017; 174: 145 doi: 10.1016/j.pharmthera.2017.02.028
5
Patrik Hidefjäll, Magnus Backheden. Making health technology assessment more dynamic – Temporal trend analysis to capture performance trajectoriesHealth Policy and Technology 2017; 6(3): 328 doi: 10.1016/j.hlpt.2017.04.005